Cg Oncology, Inc. · NASDAQ:CGON
Cg Oncology — Investor Presentation (2026)
30 slides from Cg Oncology's investor presentation, 2026
Slide 1: Attacking Bladder Cancer for a Better Tomorrow
Attacking Bladder Cancer for a Better Tomorrow | 1
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward -Looking Statements We caution you that this presentation contains forward -looking statements about us and our industry. All statements other than s tatements of historical facts contained in this presentation, including statements regarding our future results of operations a
Slide 3: The Promise of Cretostimogene
Click to edit The Promise of Master title style Cretostimogene Potential Best -in-Disease Potential Best -in-Disease Regulatory & Commercial Durability and Efficacy Safety/Tolerability Readiness ▪ BOND -003 Cohort C ( HR BCG UR ▪ Favorable safety & tolerable ▪ Granted Breakthrough Therapy & CIS only
Slide 4: Comprehensive Programs in High-Risk and Intermediate-Risk NMIBC
Comprehensive Programs in High Click to edit -Risk and Intermediate -Risk NMIBC Addressing a Multi Master title style -Billion Dollar Market Opportunity COMPOUND/INDICATION PHASE 1 PHASE 2 PHASE 3 MILESTONES Cretostimogene Monotherapy BOND -003 Cohort C High -Risk BCG -Unresponsive NMIBC (BOND -003
Slide 5: Cretostimogene's Dual Mechanism of Action
Cretostimogene’s Dual Mechanism of Action: Selective Tumor Killing Triggers Durable Anti -Tumor Immune Response Cretostimogene selectively Immune cells attack and kill 1 2 replicates in and kills cancer cells additional cancer cells 1a Progeny viruses are released and 1b Cretostimogene stimulates en
Slide 6: NMIBC Represents a Multi-Billion Dollar Market Opportunity in Bladder Cancer
NMIBC Represents a Multi -Billion Inside of the Bladder wall Outside of the bladder wall bladder wall Dollar Market Opportunity in Lamina Propria Inner Muscle Deep Muscle Bladder Cancer CIS Carcinoma in Situ (CIS) Non -Invasive Ta Papillary Carcinoma New bladder cancer cases for Non -Muscle Invasive
Slide 7: Patient Journey
Patient Journey 1 Symptoms 4 Ongoing Treatment Require surveillance and/or Patient presents to primary care treatment every 3 to 6 months and/or urologist with symptoms for 2 to 5 years (hematuria, urinary frequency) 2 Testing NMIBC Work -up may include cystoscopy, urine cytology, Low -Risk Intermed
Slide 8: Cretostimogene is Intravesically Administered, Similar to BCG
Cretostimogene is Intravesically Administered into the Bladder, Similar to Standard -of -Care BCG Therapy Which Urology Practices Perform Regularly GAG Layer Tumor Procedure Can Be Prepared and Administered By: Medical Assistant, Nurse, Nurse Practitioner, Standard DDM ~15 minutes Physician Assistan
Slide 9: Programs Address More Than 70% of NMIBC Market Potential
Cretostimogene Programs Across High -Risk & Intermediate -Risk NMIBC Address More Than 70% of NMIBC Market Potential 85K+ Bladder Cancer (U.S. Incidence) 730K+ Bladder Cancer (U.S. Prevalence ) 75% NMIBC NMIBC (75%) Intermediate -Risk (30%) High -Risk (40%) BCG -Exposed BCG -Unresponsive PIVOT -006
Slide 10: Phase 3 BOND-003 Monotherapy for HR BCG-Unresponsive NMIBC
Click to edit Phase 3 Cretostimogene Monotherapy for BOND -003 Master title style High -Risk (HR) BCG -Unresponsive NMIBC (NCT04452591) HR BCG -Unresponsive Cretostimogene CR at Any Time (CIS) NMIBC Single -Arm, Open -Label, Intravesical Administration EFS (Ta/T1) Trial Design Study Design / Regimen
Slide 11: BOND-003 Cohort C: Favorable Efficacy and Durability
ClickBOND to edit -003 Cretostimogene Demonstrated Favorable Efficacy and Master title style Cohort C Best -in-Disease Durability Data in NMIBC Overall Complete Response 100 CR Landmark CR Rate, % CR by K -M Est, % 75.5% Analysis (95% CI) (95% CI) (95% CI, 66.3% - 83.2%) 12-month 46.4% (36.8 -56.2)
Slide 12: Best-in-Disease Complete Response Rate at 24 Months
BOND -003 Cretostimogene Has Delivered Best -in-Disease Complete Click to edit Master title style Cohort C Response (CR) Rate at 24 Months Complete Response (CR) at 24 -Month ▪ Cretostimogene demonstrated 45 best -in-disease long -term DoR 40 compared to approved drugs 1 42 % 35 (46/110) in NMIBC wi
Slide 13: Well Positioned as Backbone Therapy in NMIBC
CIS with or Cretostimogene is Well Positioned as Backbone Therapy in without Ta/T1 NMIBC with Best -in-Disease Durability & Safety in HR BCG -UR 1 Trial BOND -003 COHORT C SunRISe -1 QUILT 3.032 NCT02773849 KEYNOTE -057 (Status) (Ph3 Ongoing) (Approved) (Approved) (Approved) (Approved) Drug Cretosti
Slide 14: BOND-003 Cohort P: HR BCG-Unresponsive Papillary Patients
BOND -003 Cohort P High -Risk BCG -Unresponsive Papillary (HG Ta/T1) Patients Creto High -Grade Event -Free Survival (HG -EFS) vs. DFS/RFS (by K -M) 1 ▪ BOND -003 Cohort P 100% 95.7% reported 95.7%, 84.6% and 80.4% HG Event -Free 90% 84.6% 80.4% Survival (EFS) at 3, 6 and 9 80% months, respectively
Slide 15: Well Positioned in HR BCG-UR NMIBC with HG Ta/T1 Papillary Disease
Papillary Disease Cretostimogene is Well Positioned in HR BCG -UR NMIBC with HG Ta/T1 with Potentially Best -in-Disease EFS Endpoint 1 (HG Ta/T1) Trial BOND -003 COHORT P SunRISe -1 2 QUILT 3.032 3 NCT02773849 4,5 KEYNOTE -057 6 (Status) (Ph3 Ongoing) 1 Drug Cretostimogene TAR -200 N -803 + BCG Nado
Slide 16: PIVOT-006: Adjuvant Cretostimogene for IR NMIBC
Ph 3 Adjuvant Cretostimogene for IR NMIBC, Enrollment Click to edit PIVOT -006 Master title style Completed Ahead of Schedule in Broadest Population of IR NMIBC Patients Intermediate -Risk (IR) NMIBC Cretostimogene vs Surveillance/TURBT Primary Endpoint: (Enrollment Completed) Randomized (1 :1), Two
Slide 17: PIVOT-006 Designed for Broad Intermediate-Risk Population
Intermediate -Risk PIVOT -006 Designed to Evaluate Cretostimogene in a Broad Landscape Patient Population Across Intermediate -Risk (IR) NMIBC Cretostimogene TAR -210 UGN -102 (PIVOT -006) (investigational) (MoonRIse -1) (investigational) (Approved) IR NMIBC LG Newly Diagnosed IR NMIBC LG Recurrent
Slide 18: CORE-008 Cohort CX: BCG-Exposed Combination with Gemcitabine
CORE -008 Click to edit Master title style Cohort CX Ph 2 Cretostimogene in Combination for High -Risk (HR) BCG -Exposed & BCG -Unresponsive NMIBC (Cohort CX) HR BCG -Exposed & BCG Cretostimogene + Gemcitabine Primary Endpoint: Unresponsive NMIBC 1:1 Randomized, Two Arm, Open -Label HG -EFS Populati
Slide 19: CORE-008 Cohort CX High-Grade Event-Free Survival
CORE Click to edit -008 Cohort CX High -Grade Event -Free Survival at 3 and 6 -Months (ITT Population) Master title style ▪ Median follow -up: 6.6 months ▪ No significant differences in HG - Estimated HG -EFS Estimated HG -EFS EFS by arm at Month 3 at Month 6 96.0% 89.5% ▪ Consistent response among
Slide 20: CORE-008 Cohort CX Complete Response Rates
CORE Click to edit -008 Cohort CX High Complete Response Rates Within CIS - Containing Master title style Population 92.3% 100 85.7% (95% CI, 74.9% - 99.1%) ▪ Includes BCG -Exposed and BCG Unresponsive patients - Complete Response at Any Time (%) (95% CI, 67.3% – 96.0%) ▪ 0% Grade ≥ 3 TRAEs, SAEs or
Slide 21: CORE-008 Cohort A & B: BCG-Naïve and BCG-Exposed NMIBC
CORE -008 Click to edit Phase 2 Cretostimogene Monotherapy for High -Risk (HR) Master title style Cohort A & B BCG -Naïve and BCG -Exposed NMIBC (Cohort A and B) HR BCG -Naïve & BCG -Exposed Cretostimogene Primary Endpoint: (Actively Enrolling) Two Cohorts (A and B), Two Arms Each, Open -Label CR Ra
Slide 22: High Initial Response Rates from CORE-008 Cohort A
CORE -008 Cohort A High Initial Response Rates from CORE -008 Cohort A Overall Complete Response CR Rate, % 100 83.7% CR Landmark Analysis (95% CI) (95% CI, 70.33% - 92.7%) Original Instillation 2 79.2% (57.8, 92.9) (5-step) 19 out of 24 patients 75 Overall CR Rate (%) Optimized Instillation 3 88.0%
Slide 23: Advancing Cretostimogene to Optimized Instillation
Optimized Click to edit Master title style Instillation Advancing Cretostimogene to Optimized Instillation Original Process Optimized Process ▪ Cohort A data supports optimized instillation Five -Step Two -Step ▪ Meaningful benefit to patients and sites (esp. high -volume centers) with ~20 -minute t
Slide 24: Key Clinical Metrics Driving HCP Treatment Decisions
Key Clinical Metrics Driving HCP Treatment Decisions in High- Click to edit Risk BCG-unresponsive NMIBC* Master title style Provides DoR 81% Provides CR 76% Side Effect Profile Tolerable 43% Cystectomy avoidance rates 40% Improves Patient QoL 23% Route of Administration 16% Convenient Dosing Schedul
Slide 25: Building a Capital-Efficient, High-Touch Launch Approach
CG is Building a Capital -Efficient, High -Touch Approach in Anticipation of a Successful Launch Across a Concentrated Prescriber Network Field Organization Sites Prescribers <75 Community field team Academic 47% 53% Targeting Reaching Key Account Managers Health System Directors Regional Business D
Slide 26: The Path to 150K+ Addressable Patients
The Path to 150K+ Addressable Patients Click to edit Master title style Annualized WAC of approved therapies in HR NMIBC range from $200K to $690K 160,000 CORE -008 Cohort A 140,000 CORE -008 25K Cohorts CX & B 120,000 100,000 50K 80,000 PIVOT -006 150K+ 60,000 50K 40,000 BOND -003 Cohorts C & P 20,
Slide 27: Catalyst Rich Calendar Through Potential First Approval and Launch
Anticipated Click to edit Catalyst Rich Calendar Through Potential First Approval and Master title style Milestones* Launch Followed by Frontline Bladder Indication Expansion Program 2025 2026* 2027* BOND -003 Cohort C BCG -UR CORE -008 Cohort CX BCG -Exposed CORE -008 Cohort CX BCG -Exposed Long -T
Slide 28: Contact Us
CONTACT US GENERAL INQUIRIES Information@cgoncology.com MEDIA MediaRelations@cgoncology.com www.CGOncology.com | 28
Slide 29: Executive Leadership Team
Executive Leadership Team Deep Industry Experience with Track Record of Success in Drug Development and Commercialization Arthur Kuan Swapnil Bhargava, Ph.D. Jim DeTore Vijay Kasturi, M.D. Josh Patterson, Esq. Chairman, President & Chief Technical Officer Chief Financial Officer Chief Medical Office
Slide 30: Our Vision Our Mission
Our Vision We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. Our Mission We are focused on developing Attacking Bladder Cancer bladder -sparing therapeutics for for a Better Tomorrow patients affli